Oriana Y. Yu
Montreal, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.
Journal: Annals of internal medicine
Published: August 31, 2026
Time to Insulin Initiation Among Patients With Type 2 Diabetes Treated With Second-Line Antidiabetic Drugs.
Journal: Diabetes, obesity & metabolism
Published: March 12, 2026
Balancing the benefits and risks of GLP-1 receptor agonists: a clinical guide for shared decision-making.
Journal: EClinicalMedicine
Published: December 16, 2025
Glucagon-Like Peptide 1 Receptor Agonists and Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients With Type 2 Diabetes.
Journal: Diabetes care
Published: October 21, 2025
A systematic review of observational studies of sodium-glucose cotransporter 2 inhibitors and COVID-19 outcomes: a methodological assessment.
Journal: Journal of clinical epidemiology
Published: September 18, 2025
Long-acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population-based cohort study.
Journal: Diabetes, obesity & metabolism
Published: September 10, 2025
Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study.
Journal: Diabetes, obesity & metabolism
Published: July 24, 2025
Glucagon-Like Peptide-1 Receptor Agonists and Risk for Gastroesophageal Reflux Disease in Patients With Type 2 Diabetes : A Population-Based Cohort Study.
Journal: Annals of internal medicine
Published: July 14, 2025
The association between pre-existing type 2 diabetes on cancer-related and all-cause mortality among women with breast cancer.
Journal: Breast cancer research and treatment
Published: July 08, 2025
Emulating a Randomized Controlled Trial of Long-Acting Insulins and Cardiovascular Events Using Real-World Data for Patients With Type 2 Diabetes.
Journal: Pharmacoepidemiology and drug safety
Published: June 27, 2025
Incretin-Based Drugs and the Risk of Dementia Among Patients with Type 2 Diabetes.
Journal: Drug safety
Published: May 26, 2025
Incretin-Based Drugs and the Incidence of Endometrial Cancer Among People with Type 2 Diabetes: Active Comparator New-User Design.
Journal: Drug safety
Published: April 10, 2025
Last Updated: 09/26/2026